Alnylam Pharmaceuticals / CMC Lab
300 Third Street, 2nd Floor, Cambridge, MADownload Project Profile
About the project
At the end of 2015, Alnylam undertook the expansion of an existing R&D lab in an effort to provide space to perform functions for which the lab was not previously equipped. The project entailed expanding into an existing café space, therefore extensive integration with the existing lab systems was required, notably the tie-in to the existing RO/DI (reverse osmosis/de-iodized) water lines.
The scope also included purchasing an HPLC array – a piece of equipment completely new to Alnylam. Because Alnylam didn’t have this equipment in any other laboratory, it was essential to develop new process and procedures for installation and use. The installation of a new roof top unit to support additional HVAC requirements for this highly technical piece equipment was also necessary.
Hereva was hired to manage this fast track construction project to be completed in just six weeks. This involved coordinating equipment and infrastructure shutdowns to tie into existing building systems, with coordination of multiple vendors required. Hereva was also tasked with working with lab users to coordinate all equipment deliveries and set up.
About the Client
The discovery of RNAi has been heralded as a major scientific breakthrough that happens only once every decade or so, and represents one of the most promising and rapidly advancing frontiers in biology and drug discovery today.
Alnylam was founded in 2002 on a revolutionary vision and bold mission which remain firmly in place today. Alnylam is leading the translation of RNAi as a new class of innovative medicines, with a core focus on RNAi therapeutics toward genetically defined targets for the treatment of serious, life threatening diseases with limited treatment options for patients and their care givers.